Immunology and Microbiology
Agonist
12%
Antibody-Dependent Cell-Mediated Cytotoxicity
7%
Antigen Specificity
11%
Antineoplastic Activity
22%
Atezolizumab
10%
Autoimmunity
9%
B Cell
33%
Bispecific Antibody
29%
Calreticulin
16%
Cancer Cell
61%
Cancer Immunotherapy
35%
CD20
34%
CD40 Ligand
9%
CD47
44%
CD8
12%
Cell Death
21%
Cell Line
8%
Cell Phagocytosis
11%
Cell Surface
22%
Cetuximab
10%
Cross Linking
8%
CXCL16
10%
Cytotoxic T-Cell
17%
Cytotoxicity
15%
Ecalectin
26%
Endoplasmic reticulum
8%
Epidermal Growth Factor
9%
Granulocyte
15%
Immune Response
13%
Immunotherapy
15%
Inflammatory Arthritis
17%
Lymphocyte
9%
Macrophage
24%
Monospecific Antibody
26%
Myeloid
11%
Neutrophil
13%
Neutrophil Granulocyte
9%
Normal Human
7%
Phagocytosis
25%
Rituximab
24%
Surface Property
8%
T Cell
100%
T Cell Receptor
21%
TNF related apoptosis inducing ligand
27%
Tumor Cell
14%
Tumor Immunity
9%
Tumor Necrosis Factor
23%
Tumor Necrosis Factor Receptor
13%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
7%
Tumor-Infiltrating Lymphocytes
11%
Pharmacology, Toxicology and Pharmaceutical Science
6 Diazo 5 Oxonorleucine
6%
Acute Lymphoblastic Leukemia
5%
Acute Myeloid Leukemia
22%
Antibodies
5%
Bispecific Antibody
14%
Calcium Carbonate
10%
CD40 Ligand
7%
Clinical Trial
6%
Controlled Release
6%
Cytarabine
10%
Cytotoxicity
6%
Cytotoxicity
5%
Daratumumab
6%
Death Receptor
10%
Drug Delivery System
8%
Ecalectin
10%
Elimination
34%
Enzyme-Linked Immunosorbent Assay
6%
Epidermal Growth Factor Receptor
27%
Epithelial Cell Adhesion Molecule
6%
Fas Ligand
6%
Fusion Protein
74%
Gamma Urogastrone
6%
Gemtuzumab Ozogamicin
10%
Glioblastoma
5%
Histone Deacetylase Inhibitor
6%
Immunotherapy
20%
Leukemia
13%
Malignant Neoplasm
76%
Melanoma
11%
Monoclonal Antibody
9%
Mouse
6%
Nanoparticle
21%
Neoplasm
90%
Ovary Cancer
15%
Proteinase
15%
Proteochondroitin Sulfate
9%
Receptor
8%
Rheumatoid Arthritis
6%
Rituximab
16%
Side Effect
6%
Single Chain Fragment Variable Antibody
11%
Sodium Chloride
5%
Sodium Valproate
10%
T Cell Leukemia
7%
Tissue Injury
5%
Trastuzumab
7%
Tumor Necrosis Factor
15%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
27%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand Receptor
12%
Medicine and Dentistry
Acute Myeloid Leukemia
7%
Adult T-Cell Leukemia/Lymphoma
5%
Antibody Dependent Cellular Cytotoxicity
6%
Antineoplastic Activity
30%
Autoimmunity
7%
Autophagy
10%
Bispecific Antibody
13%
Calreticulin
16%
Cancer Cell
41%
Cancer Immunotherapy
16%
Cancer Therapy
13%
CD20
9%
CD8 Antigen
5%
Cell Death
9%
Cell Surface
23%
Chimeric Antigen Receptor T-Cell
5%
Cytotoxicity
6%
Diffuse Large B-Cell Lymphoma
11%
Endoplasmic reticulum
8%
Epidermal Growth Factor Receptor
12%
Fas Ligand
6%
Fusion Protein
41%
Granulocyte
6%
Immune Checkpoint Blockade
6%
Immune Response
6%
In Vitro
8%
Krukenberg Tumor
5%
Leukemia Cell
7%
Lymphocyte
7%
Macrophage
10%
Malignant Neoplasm
38%
Monoclonal Antibody
7%
Neoplasm
29%
Neutrophil
9%
Nodular Melanoma
7%
Ovarian Cancer
16%
Overall Survival
6%
Phagocytosis
13%
Programmed Cell Death
35%
Proteinase
15%
Rituximab
15%
Single Chain Fragment Variable Antibody
6%
T Cell
45%
Target Cell
10%
Tumor Cell
15%
Tumor Immunity
8%
Tumor Infiltrating Lymphocyte
7%
Tumor Necrosis Factor
6%
Tumor Necrosis Factor Receptor
6%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
24%
